☆ 4.6 Review

Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses

Brendan Beaton et al.

Summary: Patients with indolent lymphoma undergoing B cell suppression treatment are at risk of severe COVID-19. A study found that after receiving two doses of BNT162b2 vaccine, patients had lower levels of anti-spike IgG, which correlated with lymphocyte count and treatment time. However, all cohorts showed functional T cell responses.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

添加到收藏夹

Article Immunology

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

Paolo Corradini et al.

Summary: This study investigated the immune response to the SARS-CoV-2 vaccine in patients with tumors and immune disorders. The results showed that immunosuppressive treatment was a risk factor for a low humoral response, while the booster dose improved both humoral and T-cell responses.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Letter Hematology

Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination

Margherita Rosati et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece

Evangelos Terpos et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Potentiation of humoral response to BNT162b2 vaccine after the third dose in patients with solid cancer

V. Di Noia et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy

Evangelos Terpos et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response

Patrick Reimann et al.

Summary: Patients with haemato-oncological malignancies have lower response rates to COVID-19 vaccination, with a heterologous booster vaccination showing promise in improving response rates, although efficacy varies and may result in mild adverse events.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses

Irit Avivi et al.

Summary: This prospective study evaluated the seroconversion rates in B-cell non-Hodgkin lymphoma (B-NHL) patients in response to the Pfizer-BioNTech COVID-19 vaccine booster. It found that longer time from last anti-CD20 monoclonal antibody (moAb) treatment and a diagnosis of aggressive lymphoma were associated with higher rates of seroconversion.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Ondrej Susol et al.

Summary: The mRNA COMIRNATY vaccine has been administered to 392 patients with a two-dose regimen, resulting in an overall antibody response of 70%. The initial results of administering a third dose to 80 patients who did not achieve seroconversion or had a weak response show promise, especially for patients on anti-CD38 therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Oncology

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C. Shapiro et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Immune responses following third COVID-19 vaccination are reduced in patients with hematological compared to patients with solid cancer

Annika Fendler et al.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study

Stefano Molica et al.

Summary: The antibody response to the BNT162b2 mRNA COVID-19 vaccine in CLL patients is impaired, with the highest response rate observed in treatment-naive patients and those in sustained clinical remission after therapy. However, CLL patients on certain treatments are less likely to respond well to the vaccine.

CHEMOTHERAPY (2022)

添加到收藏夹

Article Oncology

COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination

Mansi R. Shah et al.

Summary: Patients with multiple myeloma show detectable antibody responses to COVID-19 vaccines, with age, ongoing anti-CD38 mAb therapy, and receiving the J&J vaccine negatively affecting the responses.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Infectious Diseases

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

Esther Saiag et al.

Summary: Most immunosuppressed patients showed an increase in antibody levels after receiving a third dose of the Pfizer-BioNTech vaccine, although the response varied based on the type of disease and level of immunosuppression.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Infectious Diseases

Evaluation of five widely used serologic assays for antibodies to SARS- CoV-2

Christopher Stocking et al.

Summary: This study compared 5 widely used commercial methods for detecting antibodies against SARS-CoV-2, finding that IgG and total antibody detection have similar sensitivity and specificity in a similar range, but differ at high antibody titres. Including IgA antibodies increased the sensitivity to detect seroconversion.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2022)

添加到收藏夹

Article Oncology

Original Research Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study

Maximilian J. Mair et al.

Summary: This study demonstrates improved antibody levels in patients with cancer after the third vaccination dose with an acceptable side-effect profile. However, lower antibody levels compared to controls highlight the need for further follow-up studies and dedicated trials.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Hematology

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

Nico Gagelmann et al.

Summary: Vaccination against SARS-CoV-2 has shown lower antibody response in patients with hematological malignancies compared to solid cancer and healthy controls. Different types of hematological malignancies also exhibit varying outcomes. Further studies on timing, value of boosters, and long-term efficacy are warranted.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Oncology

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Valerie Gounant et al.

Summary: The study found that SARS-CoV-2 vaccines were effective in patients with thoracic cancer, with the majority being immunized after two doses. Administering a third vaccine dose to 1% of patients with persistently low antibody titers resulted in an 88% immunization rate.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Hagai Ligumsky et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer

Mariana Chavez-MacGregor et al.

Summary: This study showed that patients with recent cancer treatment and COVID-19 had significantly higher risk of adverse outcomes, while patients with no recent cancer treatment had similar outcomes to those without cancer. The findings have implications for risk stratification and resource allocation for patients, clinicians, and health systems.

JAMA ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg et al.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Maximilian J. Mair et al.

Summary: This study found that cancer patients can develop anti-SARS-CoV-2 antibodies after vaccination, but at lower levels compared to healthcare workers. Further research on vaccination effects in cancer patients is needed.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Charlotte Fenioux et al.

Summary: This study aimed to assess the immune humoral response to the BNT162b2 vaccine in patients treated with anticancer agents. The results showed that the majority of patients had a good humoral response 28 days after the second dose of vaccine, but it gradually decreased over time. The study also found that the time between vaccine and chemotherapy did not interfere with the humoral response.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis

Dimitris Papadopoulos et al.

Summary: This study used machine learning techniques to analyze data from 302 subjects and found that younger subjects had higher levels of neutralizing antibodies. Age, obesity, and autoimmune diseases had negative effects on the development of NAbs against SARS-CoV-2 nine months after vaccination.

BIOMEDICINES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

Evangelos Terpos et al.

Summary: This study compared the neutralizing antibody levels after vaccination with BNT162b2 mRNA vaccine and ChAdOx1 (AZD1222) viral vector vaccine at different time points. The results showed that BNT162b2 induced stronger neutralizing antibody responses compared to AZD1222, and both vaccines showed a gradual decline in antibody titers over time. Additionally, the rate of antibody elimination was higher in those vaccinated with AZD1222 compared to BNT162b2. Age, gender, body mass index, or comorbidities did not significantly impact antibody levels over time.

BIOMEDICINES (2022)

添加到收藏夹

Letter Hematology

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia

Zoe L. Lyski et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Editorial Material Hematology

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Cristina Bagacean et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

Moraima Jimenez et al.

Summary: Recent studies have shown that patients with hematologic malignancies have a suboptimal humoral response to SARS-CoV-2 mRNA vaccines, while data on cellular immunogenicity are limited. This study aimed to evaluate the humoral and cellular immunogenicity following the second dose of the mRNA-1273 vaccine. The results showed that 76.3% of patients developed humoral immunity and 79% had a cellular response. Factors such as hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy were associated with a poorer humoral response, while age over 65, active disease, lymphopenia, and immunosuppressive treatment for graft-versus-host disease were associated with an impaired cellular response.

BLOOD ADVANCES (2022)

添加到收藏夹

Letter Hematology

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Giovanni Caocci et al.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2

Francesco Marchesi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine

Maria Gavriatopoulou et al.

Summary: Patients with multiple myeloma have suboptimal antibody responses after vaccination against SARS-CoV-2, but show superior humoral responses compared to vaccinated individuals after contracting COVID-19.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Hematology

Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy

Thomas Gastinne et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Oncology

Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study

F. Nelli et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Muhammad Bilal Abid et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Adolfo Aleman et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

Sidse Ehmsen et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma

Julius C. Enssle et al.

CANCER CELL (2022)

添加到收藏夹

Article Hematology

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies

Ronit Gurion et al.

Summary: This study aimed to assess the humoral response of lymphoma patients after receiving two doses of BNT162b2 Pfizer vaccine and identify factors affecting the response. The results showed that lymphoma patients, especially those recently treated with anti-CD20 monoclonal antibodies, failed to develop sufficient humoral response to the vaccine. This low level of response could make them more vulnerable to COVID-19, highlighting the need for a different vaccination schedule for this population.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Infectious Diseases

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

Simon B. Gressens et al.

Summary: This study evaluated the humoral response after mRNA vaccination and the impact of a third vaccine dose in lymphoid malignancy patients. The findings showed a better humoral response in patients with plasma cell disorders compared to those with B-cell malignancies, due to the use of anti-CD20 antibodies. The third vaccine dose significantly improved humoral responses in plasma cell disorder patients, but had limited effect in B-cell malignancy patients.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Oncology

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines

Anna M. Di Giacomo et al.

Summary: Our study found a higher occurrence of SARS-CoV-2 infection in cancer patients and healthy subjects after the booster dose, with similar levels of neutralizing antibodies against all variants but with the lowest titers against the Omicron variant.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Letter Oncology

Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer

Yana Debie et al.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Letter Hematology

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

Sigrun Einarsdottir et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Immunology

SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine

Sudhir Gupta et al.

Summary: This study evaluated the T cell response to COVID-19 infection and vaccination in patients with primary antibody deficiencies. The results showed that COVID-19 infection led to higher levels of SARS-CoV-2-specific CD8 and functional CTLs in a patient with XLA, while in CVID patients, both natural infection and vaccination resulted in lower levels of these cells.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Sjoukje F. Oosting et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Oncology

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler et al.

Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Immunology

SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

Angelika Wagner et al.

Summary: This study investigated the persistence and anamnestic responses following SARS-CoV-2 mRNA vaccinations in individuals with secondary immunodeficiencies. The results suggest that primary mRNA vaccination can induce antibody responses, but some patients may experience a decline in antibody levels. Booster vaccination significantly increases antibody levels and induces anamnestic responses, but certain medications may affect the antibody response.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination

Lorenz Schubert et al.

Summary: This study confirms that both humoral and cellular responses are lower in hematological patients compared to controls, and highlights the specific response in risk groups such as CAR-T cell recipients. Anti-CD20 therapy is identified as a major risk factor for poor humoral response. CD19(+) B-cell and CD4(+) T-cell levels are additional predictive markers for seroconversion. The study also suggests that a decline in antibodies occurs over a six-month period in both responders and controls, raising the question of whether third vaccination is beneficial for non-responders to the second dose.

CANCERS (2022)

添加到收藏夹

Article Oncology

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

A. Lasagna et al.

Summary: This study aimed to evaluate the immunogenicity of the third dose of mRNA vaccine in cancer patients undergoing treatment. The results showed that the third dose was able to trigger both the cell-mediated and humoral immune response in cancer patients. Preliminary data also indicated lower neutralizing activity of the vaccine against new variants.

ESMO OPEN (2022)

添加到收藏夹

Article Hematology

SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies

Evangelos Terpos et al.

Summary: Patients with B-cell malignancies have suboptimal immune responses to SARS-CoV-2 vaccination, but a third booster dose can enhance the antibody response in some patients.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies

Thomas A. Ollila et al.

Summary: Patients with hematologic malignancies have reduced response to COVID-19 vaccination, but booster vaccinations can improve seroconversion rate. Prophylactic antibody therapy can prevent COVID-19 infection and death.

CANCER (2022)

添加到收藏夹

Letter Hematology

SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia

Sibylle C. Mellinghoff et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Oncology

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination

Margherita Rosati et al.

Summary: Upon BNT162b2 mRNA vaccinations, patients with multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) on active therapy had impaired antibody response to the wildtype Wuhan strain and the Omicron variant BA.4/5. However, repeat vaccination showed an improved neutralizing antibody response in these patients.

CANCERS (2022)

添加到收藏夹

Article Immunology

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Ramin Sedaghat Herati et al.

Summary: Anti-PD-1 immunotherapy has dynamic effects on noncancer immune responses, enhancing the Tfh-B cell axis response to influenza vaccination and potentially affecting immune predisposition.

NATURE IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition

Evangelos Terpos et al.

Summary: This study aimed to investigate the immunogenicity of different vaccines in cancer patients receiving immunotherapy. The results showed that a third booster dose significantly optimized antibody responses. The study highlights the importance of large cohort studies to evaluate vaccine effectiveness and durability of protection in the real-world setting.

CANCERS (2022)

添加到收藏夹

Article Oncology

Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy

Simona Gossi et al.

Summary: Limited data is available on the efficacy of SARS-CoV-2 mRNA vaccinations in patients with CAR-T-cell therapy. This study analyzed the response to BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccination in patients undergoing CAR-T-cell therapy. The results showed that patients with more B-cells and fewer CAR-T-cells at vaccination were more likely to produce a positive antibody test result. Additional vaccine doses increased seroconversion rates and antibody titers.

CANCERS (2022)

添加到收藏夹

Article Immunology

Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies

Amy C. Sherman et al.

Summary: Lymphoid malignancy patients have poorer immune responses to vaccines, but a 3-dose mRNA vaccine series can enhance anti-S IgG responses, with the third dose converting some previously seronegative patients.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine

Andrea Galitzia et al.

Summary: Patients with CLL have a low effective response rate to the BNT162b2 vaccine, but there may be some response in certain patients after the third dose, highlighting the need for further research.

VACCINES (2022)

添加到收藏夹

Article Oncology

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

A. Lasagna et al.

Summary: The immunogenicity of the third dose of the COVID-19 vaccine in cancer patients, especially against variants of concern, needs further investigation. This study prospectively evaluated the immune response triggered by the mRNA vaccine BNT162b2 in patients with solid tumors 6 months after receiving the booster dose. The results show a significant humoral and cellular immune response, although there is a reduced neutralizing activity against the Omicron variant.

ESMO OPEN (2022)

添加到收藏夹

Letter Hematology

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Lisa Blixt et al.

BLOOD (2022)

添加到收藏夹

Article Hematology

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Andres Chang et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

添加到收藏夹

Article Hematology

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study

Frédérique St-Pierre et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

添加到收藏夹

Article Hematology

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL

Emily Bryer et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

添加到收藏夹

Review Immunology

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies

Maryam Noori et al.

Summary: The findings suggest a significantly lower seroprotection rate in patients with hematological malignancies compared to solid tumor patients and healthy individuals after COVID-19 vaccination. Additional booster doses may be needed to enhance immunity among these patients.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Virology

Early detection of COVID-19 outbreaks using textual analysis of electronic medical records

Michael Shapiro et al.

Summary: The study aimed to develop a textual analysis based algorithm for early detection of COVID-19 cases by focusing epidemiological investigations and PCR examinations. The algorithm successfully detected several clusters of cases that were previously unnoticed in 92 randomly selected units.

JOURNAL OF CLINICAL VIROLOGY (2022)

添加到收藏夹

Article Oncology

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response

Paola Storti et al.

Summary: The humoral and cellular response to SARS-CoV-2 vaccination is reduced in patients with multiple myeloma. Spike variants, especially Omicron, have a significant negative impact on the neutralizing ability of vaccine-induced antibodies. Heterologous booster immunization improves the response in newly diagnosed MM patients, but Omicron still poses challenges for patients with relapsed-refractory disease.

ONCOIMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Sabine Haggenburg et al.

Summary: This study aimed to assess the effectiveness of a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers. The results showed that a third vaccination had a significant effect in patients with recovering immune systems, but yielded poorer results in certain specific patient groups. Therefore, the administration of a third dose of vaccine should be considered in patients with hematologic cancers and evaluated on an individual basis.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Immunology

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents

Flora Zagouri et al.

Summary: Administration of a third dose of a vaccine against SARS-CoV-2 enhances protection in cancer patients receiving targeted therapies. Neutralizing antibody levels were lower in cancer patients compared to healthy individuals, but increased after the third dose. Antibody titers waned over time but remained above protective levels at 6 months post-second dose.

VACCINES (2022)

添加到收藏夹

Article Oncology

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

E. Su et al.

Summary: This study evaluated the immune response of cancer patients after mRNA vaccine administration and found that a booster dose can enhance the immune response, overcoming the influence of baseline and treatment factors. Breakthrough infections in the vaccinated high-risk population were generally mild.

ESMO OPEN (2022)

添加到收藏夹

Article Hematology

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients

Muneyoshi Kimura et al.

Summary: In this study, the cell-mediated and humoral immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule in allogeneic stem cell transplant recipients was investigated. The results showed that the third dose of the vaccine was associated with better humoral and cellular immune responses without increasing the risk of graft-versus-host disease (GVHD) or severe adverse effects.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

Letter Hematology

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals

Ioannis Ntanasis-Stathopoulos et al.

HEMASPHERE (2022)

添加到收藏夹

Article Oncology

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

Sean H. Lim et al.

Summary: Patients with hematological malignancies, especially those undergoing active anticancer treatment or on anti-CD20 therapy, show compromised immune responses to COVID-19 vaccination. However, booster vaccination can significantly improve antibody responses in indolent B-cell lymphoma patients, and antigen-specific T-cell responses are observed in the majority of patients after a third dose, regardless of their cancer treatment status.

NATURE CANCER (2022)

添加到收藏夹

Article Hematology

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

Evangelos Terpos et al.

Summary: This study aimed to evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months. The results showed a gradual decline in NAbs and anti-S-RBD IgGs levels from 2 weeks to 9 months postvaccination. Age was found to have a significant impact on the clearance of NAbs during the first-trimester postvaccination. Simulation studies predicted a decrease in median NAb values at 12 and 18 months postvaccination.

HEMASPHERE (2022)

添加到收藏夹

Article Oncology

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Sabine Haggenburg et al.

Summary: This study found that a third dose of mRNA-1273 vaccine can increase neutralizing antibody concentrations in immunocompromised patients with hematologic cancers, especially in those with recovering immune systems.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Ross S. Greenberg et al.

Summary: The study found that patients with multiple myeloma who received two doses of SARS-CoV-2 mRNA vaccine had low rates of adverse reactions and high rates of antibody seroconversion. These findings provide reassurance to multiple myeloma patients who are hesitant to receive the vaccine.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Flora Zagouri et al.

Summary: Breast cancer patients receiving CDK4/6 inhibitors showed similar immune responses to vaccination as healthy controls, with no safety concerns raised. Further exploration is needed to reduce uncertainty regarding SARS-CoV-2 immunity in cancer patients undergoing treatment.

BREAST (2021)

添加到收藏夹

Review Infectious Diseases

An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies

Hin Fung Tsang et al.

Summary: The transmission of COVID-19 remains uncontrollable, with increasing numbers of confirmed and death cases reported worldwide. There is currently no specific antiviral treatment for COVID-19, and treatment guidelines vary between countries. However, combination therapies and repurposing FDA-approved drugs show promise in clinical improvement for severe COVID-19 patients. Generating an ecosystem with effective protection, precautions, and preventive measures is crucial in the absence of specific treatment and vaccines for COVID-19.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

添加到收藏夹

Article Oncology

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Vincenzo Di Noia et al.

Summary: The study demonstrated that the BNT162b2 vaccine is immunogenic and safe in cancer patients. The second dose is necessary for achieving a satisfactory humoral response.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

David J. Pinato et al.

Summary: This article is a retrospective registry study involving a large number of authors and their collaborative research outcomes.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence

Sayeeda Rahman et al.

Summary: The COVID-19 pandemic has caused a public health crisis, infecting millions and leading to numerous deaths. The virus spreads rapidly through direct person-to-person respiratory transmission. With no proven treatments, current clinical management focuses on symptom control, infection prevention, supportive care, and ICU support for severe cases. Developing an effective vaccine is a top priority, with some already approved for prevention.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

Supportive care in patients with cancer during the COVID-19 pandemic

M. Aapro et al.

Summary: Cancer care has faced unprecedented challenges during the global COVID-19 pandemic, with supportive care being crucial for managing complications and minimizing hospital visits. Medical oncology societies are providing updated guidelines to help healthcare professionals devise and modify supportive care strategies for cancer patients during the pandemic.

ESMO OPEN (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

Cong Zeng et al.

Summary: Cancer patients, especially those with CLL and NHL, exhibit lower neutralizing antibody responses after receiving two doses of mRNA vaccines, indicating an urgent need for novel immunization strategies against SARS-CoV-2.

CELL AND BIOSCIENCE (2021)

添加到收藏夹

Letter Oncology

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

R. Palich et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Review Immunology

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Alessandro Allegra et al.

Summary: Secondary immunodeficiency is common in patients with hematological malignancies, affecting their risk of infection and overall prognosis. Treatment strategies need to be personalized based on individual clinical and immunological conditions, with potential risks associated with vaccination such as decreased immune response and adverse reactions.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Microbiology

Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays

Emelissa J. Valcourt et al.

Summary: The study validated a SARS-CoV-2 PRNT and utilized it as a reference standard to evaluate various serological methods for measuring SARS-CoV-2 neutralizing antibodies, demonstrating excellent agreement with the reference-standard PRNT, including high-throughput platforms.

MICROBIOLOGY SPECTRUM (2021)

添加到收藏夹

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

A. Lasagna et al.

Summary: The study demonstrated that cancer patients who received a full course of BNT162b2 vaccine generated a sustained immune response against SARS-CoV-2, regardless of prior exposure to the virus, with a significant increase in neutralizing antibody levels.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al.

Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Editorial Material Hematology

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Sarah Bird et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

Evangelos Terpos et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Serologic response to mRNA COVID-19 vaccination in lymphoma patients

Eric Matthew Jurgens et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

添加到收藏夹

Letter Hematology

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies

Thomas A. Fox et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients

Magdalena Benda et al.

Summary: The study evaluated the serological response, predictive markers, and safety of BNT162b2 in haemato-oncological patients. Results showed that over 70% of oncological patients and around 70% of haematological patients developed antibodies after vaccination, with some patients at risk of serological non-response. Vaccination was well tolerated with low risk of severe side effects.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Irit Avivi et al.

Summary: This single-centre study found that multiple myeloma (MM) patients had a lower seropositive response rate to the BNT162b2 vaccine compared to healthy controls, with older age, hypogammaglobulinaemia, and exposure to multiple anti-myeloma drugs associated with lower response rates. The vaccine was found to be safe and provide high seropositivity in MM patients independent of treatment type.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Onima Chowdhury et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

Mario Mairhofer et al.

CANCER CELL (2021)

添加到收藏夹

Article Medical Laboratory Technology

Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine

Silvia Meschi et al.

Summary: The study found a significant correlation between antibody response and virus neutralization titer, with 2,000 BAU/mL serving as a predictive threshold for strong neutralization response in vaccinated individuals.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy

Luigi Cavanna et al.

Summary: The study showed that vaccination with BNT162b2 or mRNA-1273 vaccines was safe and effective in adult patients with solid cancer, with a 75.88% seropositivity rate among patients. No Grade 3-4 side-effects or COVID-19 infections were reported, indicating good safety and immunogenicity of the vaccines in this population.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Letter Oncology

COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients

Giovanni Del Poeta et al.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Evangelos Terpos et al.

Summary: The SARS-CoV-2 vaccination provides significant protection, but cancer patients under systemic therapy show lower levels of neutralizing antibodies compared to healthy individuals, particularly those receiving Immune Checkpoint Inhibitors. This discrepancy should be taken into consideration for patients undergoing treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

添加到收藏夹

Letter Oncology

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington et al.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

添加到收藏夹

Letter Oncology

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies

Daniel Re et al.

LEUKEMIA & LYMPHOMA (2021)

添加到收藏夹

Review Oncology

Vaccination of cancer patients against COVID-19: towards the end of a dilemma

Avik Mandal et al.

Summary: With the global emergence of the second wave of COVID-19 infections, vaccination has become crucial. Vaccines have shown to reduce severe illness risk, while cancer patients face added vulnerability to the infection. However, doubts and misconceptions about vaccination during cancer treatment exist.

MEDICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

Serological response to COVID-19 vaccination in patients with cancer older than 80 years

Daniela Iacono et al.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos et al.

Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease

Thomas A. Ollila et al.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh et al.

Summary: The study showed that 90% of patients with cancer undergoing treatment had an adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research is needed to explore the clinical relevance and durability of these lower titers.

JAMA ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

BCMA in Multiple Myeloma-A Promising Key to Therapy

Martina Kleber et al.

Summary: Despite the progress in developing new agents for multiple myeloma, it remains an incurable disease. Targeting B-cell maturation antigen (BMCA) offers a promising therapeutic approach due to its high expression in mature B-lymphocytes and plasma cells. Clinical trials utilizing BMCA targeted treatments like ADCs, BITEs, and CAR T cell therapy are underway and have the potential to improve outcomes for MM patients.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study

Evangelos Terpos et al.

Summary: The urgency of the COVID-19 pandemic has accelerated vaccine development, but patients with hematological malignancies show suboptimal immune response to the SARS-CoV-2 vaccine, highlighting the need for timely vaccination during a treatment-free period and continuous vigilance on infection control measures.

CANCERS (2021)

添加到收藏夹

Article Oncology

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+B-Lymphocyte Count and Anti-CD38 Treatment

Susanne Ghandili et al.

Summary: The global impact of the COVID-19 pandemic has prompted rapid development of multiple anti-SARS-CoV-2 vaccines. Data on the efficacy of these vaccines in patients with hematological malignancies, especially plasma cell neoplasia, are limited. An observational study of 82 patients with multiple myeloma and related plasma cell neoplasia found that 23% had positive SARS-CoV-2 spike protein antibody titers after the first vaccination. Higher CD19+ B lymphocyte counts and treatment with anti-CD38 antibodies were associated with significantly higher antibody titers, while older age and poorly controlled disease correlated negatively with antibody levels. Majorities of these patients may require booster vaccinations due to poor initial response.

CANCERS (2021)

添加到收藏夹

Article Oncology

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

Helena Linardou et al.

Summary: In cancer patients, despite a high seropositivity rate after receiving two vaccine doses, their antibody titers were significantly lower compared to healthy controls. Monitoring immune responses and understanding clinical factors influencing immunity could aid in adjusting vaccination strategies for vulnerable subgroups.

CANCERS (2021)

添加到收藏夹

Letter Medicine, General & Internal

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Amandine Le Bourgeois et al.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Hematology

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study

Maria Gavriatopoulou et al.

Summary: Immunocompromised patients with hematologic malignancies, particularly those with Waldenstroeurom macroglobulinemia (WM), have lower production of neutralizing antibodies (NAbs) against SARS-CoV-2 after COVID-19 vaccination compared with healthy controls on days 22 and 50 post-vaccination. Disease-related immune dysregulation and therapy-related immunosuppression are likely contributors to this suboptimal humoral response. Active treatment with specific medications is also associated with a diminished antibody response following vaccination.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry et al.

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Oncology

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: Patients with cancer have higher morbidity and mortality when infected with COVID-19. The CAPTURE study found that while most patients had immune responses against the original SARS-CoV-2, neutralizing antibody titers against variants were significantly reduced, with some patients experiencing a decrease in antibody levels. However, neutralizing antibody titers remained stable for some patients.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung et al.

Summary: Patients with hematologic malignancy have compromised COVID-19 vaccine responses at baseline, which are further suppressed by certain therapies, leading to insufficient neutralizing capacity despite positive antibody titers. Refining vaccine response parameters is critical for guiding clinical care, including the consideration for booster vaccines in this vulnerable population.

BLOOD CANCER DISCOVERY (2021)

添加到收藏夹

Article Hematology

Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients

Sandra Easdale et al.

Summary: Immunocompromised patients, especially those who have undergone allogeneic hematopoietic cell transplantation, show inferior antibody responses to SARS-CoV-2 vaccines. Older age and concurrent use of immunosuppressive medications significantly impact the antibody response to vaccination. Further research is needed to develop more effective vaccine formulations for these high-risk patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Oncology

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy

Roni Tamari et al.

Summary: Cellular therapies render patients severely immunocompromised, and this study highlights the importance of vaccination against COVID-19 in this vulnerable population. Predictors of response to vaccination, such as time from therapy to vaccination and immune recovery post-therapy, are crucial in informing clinical decisions about optimal timing of vaccines and the need for booster doses.

BLOOD CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

Josef Singer et al.

Summary: Vaccination is the primary public health strategy to combat the COVID-19 pandemic, with solid tumor and hematologic patients being at higher risk of severe complications. Data on immune responses to COVID-19 vaccines in these patients are scarce. Complete vaccination is a valuable predictor for high anti-SARS-CoV-2 antibody responses in these vulnerable patient groups.

CANCERS (2021)

添加到收藏夹

Letter Hematology

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis

Efstathios Kastritis et al.

HEMASPHERE (2021)

添加到收藏夹

Review Oncology

Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence

Elissar Moujaess et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

添加到收藏夹

Article Hematology

Increased expression of CD8 marker on T -cells in COVID-19 patients

Ali Ganji et al.

BLOOD CELLS MOLECULES AND DISEASES (2020)

添加到收藏夹

Review Oncology

COVID-19 in cancer patients: risk, clinical features, and management

Cuiwei Liu et al.

CANCER BIOLOGY & MEDICINE (2020)

添加到收藏夹

Review Allergy

Hepatitis B vaccine nonresponders Possible mechanisms and solutions

Tara Vinyette Saco et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.